APO Research
Talk to an analyst

APO RESEARCH · REPORT

Topical Drugs CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Topical Drugs CDMO Market Analysis and Forecast 2026-2032

30 December 2025196 pages

Choose your research edition.

Industry ResearchTopical Drugs CDMO Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Topical Drugs CDMO Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Topical Drugs CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Topical Drugs CDMO Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Topical Drugs CDMO Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Topical Drugs CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Topical Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Topical Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Topical Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Topical Drugs CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Topical Drugs CDMO include Piramal Pharma Solutions, Pierre Fabre Group, PCI Pharma Services, MedPharm Ltd., Lubrizol Life Science, DPT Laboratories LTD., Contract Pharmaceuticals Limited, Cambrex Corporation and Bora Pharmaceutical CDMO, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Topical Drugs CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Topical Drugs CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Topical Drugs CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Topical Drugs CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Topical Drugs CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Topical Drugs CDMO revenue, projected growth trends, production technology, application and end-user industry.

Topical Drugs CDMO Segment by Company

Piramal Pharma Solutions

Pierre Fabre Group

PCI Pharma Services

MedPharm Ltd.

Lubrizol Life Science

DPT Laboratories LTD.

Contract Pharmaceuticals Limited

Cambrex Corporation

Bora Pharmaceutical CDMO

Ascendia Pharmaceuticals

Topical Drugs CDMO Segment by Type

Contract Development

Contract Manufacturing

Topical Drugs CDMO Segment by Application

Semi-Solid Formulations

Solid Formulations

Liquid Formulations

Others

Topical Drugs CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Topical Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Drugs CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Topical Drugs CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Topical Drugs CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Topical Drugs CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Topical Drugs CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Contract Development Major Player Table 3. Contract Manufacturing Major Player Table 4. Global Topical Drugs CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Semi-Solid Formulations Major Player Table 6. Solid Formulations Major Player Table 7. Liquid Formulations Major Player Table 8. Others Major Player Table 9. Topical Drugs CDMO Industry Trends Table 10. Topical Drugs CDMO Industry Drivers Table 11. Topical Drugs CDMO Industry Opportunities and Challenges Table 12. Topical Drugs CDMO Industry Restraints Table 13. Global Topical Drugs CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Topical Drugs CDMO Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Topical Drugs CDMO Market Share by Region (2021-2026) Table 16. Global Topical Drugs CDMO Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Topical Drugs CDMO Market Share by Region (2027-2032) Table 18. Global Topical Drugs CDMO Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Topical Drugs CDMO Revenue Market Share by Players (2021-2026) Table 20. Global Topical Drugs CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Topical Drugs CDMO Key Players Headquarters & Area Served Table 22. Global Topical Drugs CDMO Players, Product Type & Application Table 23. Global Topical Drugs CDMO Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Topical Drugs CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Topical Drugs CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Topical Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Topical Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Topical Drugs CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Topical Drugs CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Topical Drugs CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Topical Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Topical Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Topical Drugs CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Topical Drugs CDMO Revenue Market Share by Application (2027-2032) Table 36. Piramal Pharma Solutions Company Information Table 37. Piramal Pharma Solutions Business Overview Table 38. Piramal Pharma Solutions Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio Table 40. Piramal Pharma Solutions Recent Development Table 41. Pierre Fabre Group Company Information Table 42. Pierre Fabre Group Business Overview Table 43. Pierre Fabre Group Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Pierre Fabre Group Topical Drugs CDMO Product Portfolio Table 45. Pierre Fabre Group Recent Development Table 46. PCI Pharma Services Company Information Table 47. PCI Pharma Services Business Overview Table 48. PCI Pharma Services Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. PCI Pharma Services Topical Drugs CDMO Product Portfolio Table 50. PCI Pharma Services Recent Development Table 51. MedPharm Ltd. Company Information Table 52. MedPharm Ltd. Business Overview Table 53. MedPharm Ltd. Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. MedPharm Ltd. Topical Drugs CDMO Product Portfolio Table 55. MedPharm Ltd. Recent Development Table 56. Lubrizol Life Science Company Information Table 57. Lubrizol Life Science Business Overview Table 58. Lubrizol Life Science Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Lubrizol Life Science Topical Drugs CDMO Product Portfolio Table 60. Lubrizol Life Science Recent Development Table 61. DPT Laboratories LTD. Company Information Table 62. DPT Laboratories LTD. Business Overview Table 63. DPT Laboratories LTD. Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio Table 65. DPT Laboratories LTD. Recent Development Table 66. Contract Pharmaceuticals Limited Company Information Table 67. Contract Pharmaceuticals Limited Business Overview Table 68. Contract Pharmaceuticals Limited Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio Table 70. Contract Pharmaceuticals Limited Recent Development Table 71. Cambrex Corporation Company Information Table 72. Cambrex Corporation Business Overview Table 73. Cambrex Corporation Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Cambrex Corporation Topical Drugs CDMO Product Portfolio Table 75. Cambrex Corporation Recent Development Table 76. Bora Pharmaceutical CDMO Company Information Table 77. Bora Pharmaceutical CDMO Business Overview Table 78. Bora Pharmaceutical CDMO Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio Table 80. Bora Pharmaceutical CDMO Recent Development Table 81. Ascendia Pharmaceuticals Company Information Table 82. Ascendia Pharmaceuticals Business Overview Table 83. Ascendia Pharmaceuticals Topical Drugs CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio Table 85. Ascendia Pharmaceuticals Recent Development Table 86. North America Topical Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 87. North America Topical Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 88. North America Topical Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 89. North America Topical Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 90. North America Topical Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America Topical Drugs CDMO Revenue by Country (2021-2026) & (US$ Million) Table 92. North America Topical Drugs CDMO Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe Topical Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe Topical Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe Topical Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe Topical Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe Topical Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe Topical Drugs CDMO Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe Topical Drugs CDMO Revenue by Country (US$ Million) & (2027-2032) Table 100. China Topical Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 101. China Topical Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 102. China Topical Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 103. China Topical Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Topical Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia Topical Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia Topical Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia Topical Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Topical Drugs CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia Topical Drugs CDMO Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia Topical Drugs CDMO Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA Topical Drugs CDMO Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA Topical Drugs CDMO Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA Topical Drugs CDMO Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA Topical Drugs CDMO Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA Topical Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA Topical Drugs CDMO Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA Topical Drugs CDMO Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Topical Drugs CDMO Image Figure 2. Global Topical Drugs CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Topical Drugs CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Contract Development Image Figure 5. Contract Manufacturing Image Figure 6. Global Topical Drugs CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Topical Drugs CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 8. Semi-Solid Formulations Image Figure 9. Solid Formulations Image Figure 10. Liquid Formulations Image Figure 11. Others Image Figure 12. Global Topical Drugs CDMO Market Size (US$ Million) & (2021-2032) Figure 13. Global Topical Drugs CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Topical Drugs CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Topical Drugs CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Topical Drugs CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Topical Drugs CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Topical Drugs CDMO Revenue Market Share by Type (2021-2032) Figure 20. Global Topical Drugs CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Topical Drugs CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Topical Drugs CDMO Revenue Market Share by Application (2021-2032) Figure 23. North America Topical Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Topical Drugs CDMO Revenue Share by Type (2021-2032) Figure 25. North America Topical Drugs CDMO Revenue Share by Application (2021-2032) Figure 26. North America Topical Drugs CDMO Revenue Share by Country (2021-2032) Figure 27. United States Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Topical Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Topical Drugs CDMO Revenue Share by Type (2021-2032) Figure 32. Europe Topical Drugs CDMO Revenue Share by Application (2021-2032) Figure 33. Europe Topical Drugs CDMO Revenue Share by Country (2021-2032) Figure 34. Germany Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Topical Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Topical Drugs CDMO Revenue Share by Type (2021-2032) Figure 44. China Topical Drugs CDMO Revenue Share by Application (2021-2032) Figure 45. Asia Topical Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Topical Drugs CDMO Revenue Share by Type (2021-2032) Figure 47. Asia Topical Drugs CDMO Revenue Share by Application (2021-2032) Figure 48. Asia Topical Drugs CDMO Revenue Share by Region (2021-2032) Figure 49. Japan Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Topical Drugs CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Topical Drugs CDMO Revenue Share by Type (2021-2032) Figure 57. SAMEA Topical Drugs CDMO Revenue Share by Application (2021-2032) Figure 58. SAMEA Topical Drugs CDMO Revenue Share by Country (2021-2032) Figure 59. Brazil Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Topical Drugs CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Contract Development
  • Contract Manufacturing
Applications
  • Semi-Solid Formulations
  • Solid Formulations
  • Liquid Formulations
  • Others
Companies covered
  • Piramal Pharma Solutions
  • Pierre Fabre Group
  • PCI Pharma Services
  • MedPharm Ltd.
  • Lubrizol Life Science
  • DPT Laboratories LTD.
  • Contract Pharmaceuticals Limited
  • Cambrex Corporation
  • Bora Pharmaceutical CDMO
  • Ascendia Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Topical Drugs CDMO Market by Type
  3. 1.2.1 Global Topical Drugs CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Contract Development
  5. 1.2.3 Contract Manufacturing
  6. 1.3 Topical Drugs CDMO Market by Application
  7. 1.3.1 Global Topical Drugs CDMO Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Semi-Solid Formulations
  9. 1.3.3 Solid Formulations
  10. 1.3.4 Liquid Formulations
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Topical Drugs CDMO Market Dynamics
  1. 2.1 Topical Drugs CDMO Industry Trends
  2. 2.2 Topical Drugs CDMO Industry Drivers
  3. 2.3 Topical Drugs CDMO Industry Opportunities and Challenges
  4. 2.4 Topical Drugs CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Topical Drugs CDMO Market Perspective (2021-2032)
  2. 3.2 Global Topical Drugs CDMO Growth Trends by Region
  3. 3.2.1 Global Topical Drugs CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Topical Drugs CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Topical Drugs CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Topical Drugs CDMO Revenue by Players
  2. 4.1.1 Global Topical Drugs CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Topical Drugs CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Topical Drugs CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Topical Drugs CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Topical Drugs CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Topical Drugs CDMO Players, Product Type & Application
  8. 4.5 Global Topical Drugs CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Topical Drugs CDMO Market CR5 and HHI
  11. 4.6.3 2025 Topical Drugs CDMO Tier 1, Tier 2, and Tier 3
5 Topical Drugs CDMO Market Size by Type
  1. 5.1 Global Topical Drugs CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Topical Drugs CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Topical Drugs CDMO Revenue Market Share by Type (2021-2032)
6 Topical Drugs CDMO Market Size by Application
  1. 6.1 Global Topical Drugs CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Topical Drugs CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Topical Drugs CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Piramal Pharma Solutions
  2. 7.1.1 Piramal Pharma Solutions Company Information
  3. 7.1.2 Piramal Pharma Solutions Business Overview
  4. 7.1.3 Piramal Pharma Solutions Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio
  6. 7.1.5 Piramal Pharma Solutions Recent Developments
  7. 7.2 Pierre Fabre Group
  8. 7.2.1 Pierre Fabre Group Company Information
  9. 7.2.2 Pierre Fabre Group Business Overview
  10. 7.2.3 Pierre Fabre Group Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pierre Fabre Group Topical Drugs CDMO Product Portfolio
  12. 7.2.5 Pierre Fabre Group Recent Developments
  13. 7.3 PCI Pharma Services
  14. 7.3.1 PCI Pharma Services Company Information
  15. 7.3.2 PCI Pharma Services Business Overview
  16. 7.3.3 PCI Pharma Services Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 PCI Pharma Services Topical Drugs CDMO Product Portfolio
  18. 7.3.5 PCI Pharma Services Recent Developments
  19. 7.4 MedPharm Ltd.
  20. 7.4.1 MedPharm Ltd. Company Information
  21. 7.4.2 MedPharm Ltd. Business Overview
  22. 7.4.3 MedPharm Ltd. Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 MedPharm Ltd. Topical Drugs CDMO Product Portfolio
  24. 7.4.5 MedPharm Ltd. Recent Developments
  25. 7.5 Lubrizol Life Science
  26. 7.5.1 Lubrizol Life Science Company Information
  27. 7.5.2 Lubrizol Life Science Business Overview
  28. 7.5.3 Lubrizol Life Science Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Lubrizol Life Science Topical Drugs CDMO Product Portfolio
  30. 7.5.5 Lubrizol Life Science Recent Developments
  31. 7.6 DPT Laboratories LTD.
  32. 7.6.1 DPT Laboratories LTD. Company Information
  33. 7.6.2 DPT Laboratories LTD. Business Overview
  34. 7.6.3 DPT Laboratories LTD. Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio
  36. 7.6.5 DPT Laboratories LTD. Recent Developments
  37. 7.7 Contract Pharmaceuticals Limited
  38. 7.7.1 Contract Pharmaceuticals Limited Company Information
  39. 7.7.2 Contract Pharmaceuticals Limited Business Overview
  40. 7.7.3 Contract Pharmaceuticals Limited Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio
  42. 7.7.5 Contract Pharmaceuticals Limited Recent Developments
  43. 7.8 Cambrex Corporation
  44. 7.8.1 Cambrex Corporation Company Information
  45. 7.8.2 Cambrex Corporation Business Overview
  46. 7.8.3 Cambrex Corporation Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Cambrex Corporation Topical Drugs CDMO Product Portfolio
  48. 7.8.5 Cambrex Corporation Recent Developments
  49. 7.9 Bora Pharmaceutical CDMO
  50. 7.9.1 Bora Pharmaceutical CDMO Company Information
  51. 7.9.2 Bora Pharmaceutical CDMO Business Overview
  52. 7.9.3 Bora Pharmaceutical CDMO Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio
  54. 7.9.5 Bora Pharmaceutical CDMO Recent Developments
  55. 7.10 Ascendia Pharmaceuticals
  56. 7.10.1 Ascendia Pharmaceuticals Company Information
  57. 7.10.2 Ascendia Pharmaceuticals Business Overview
  58. 7.10.3 Ascendia Pharmaceuticals Topical Drugs CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio
  60. 7.10.5 Ascendia Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Topical Drugs CDMO Revenue (2021-2032)
  2. 8.2 North America Topical Drugs CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Topical Drugs CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Topical Drugs CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Topical Drugs CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Topical Drugs CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Topical Drugs CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Topical Drugs CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Topical Drugs CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Topical Drugs CDMO Revenue by Country
  11. 8.6.1 North America Topical Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Topical Drugs CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Topical Drugs CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Topical Drugs CDMO Revenue (2021-2032)
  2. 9.2 Europe Topical Drugs CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Topical Drugs CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Topical Drugs CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Topical Drugs CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Topical Drugs CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Topical Drugs CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Topical Drugs CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Topical Drugs CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Topical Drugs CDMO Revenue by Country
  11. 9.6.1 Europe Topical Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Topical Drugs CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Topical Drugs CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Topical Drugs CDMO Revenue (2021-2032)
  2. 10.2 China Topical Drugs CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Topical Drugs CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Topical Drugs CDMO Revenue by Type (2027-2032)
  5. 10.3 China Topical Drugs CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Topical Drugs CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Topical Drugs CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Topical Drugs CDMO Revenue by Application (2027-2032)
  9. 10.5 China Topical Drugs CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Topical Drugs CDMO Revenue (2021-2032)
  2. 11.2 Asia Topical Drugs CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Topical Drugs CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Topical Drugs CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Topical Drugs CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Topical Drugs CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Topical Drugs CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Topical Drugs CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Topical Drugs CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Topical Drugs CDMO Revenue by Country
  11. 11.6.1 Asia Topical Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Topical Drugs CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Topical Drugs CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Topical Drugs CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Topical Drugs CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Topical Drugs CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Topical Drugs CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Topical Drugs CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Topical Drugs CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Topical Drugs CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Topical Drugs CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Topical Drugs CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Topical Drugs CDMO Revenue by Country
  11. 12.6.1 SAMEA Topical Drugs CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Topical Drugs CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Topical Drugs CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst